Therefore, relying on this study to provide ‘real-world’ risk of LRR by RS category is justifiable, particularly when the capabilities of RS in predicting LRR in early-stage ER+/HER2− breast cancer is likely being underestimated (and subsequently underutilized) in establishing LRR in high-risk cases. The gene discussed is ESR1; the disease is breast carcinoma.